Back to Search
Start Over
Real-world efficacy of brentuximab vedotin plus bendamustine as a bridge to autologous hematopoietic stem cell transplantation in primary refractory or relapsed classical Hodgkin lymphoma
- Source :
- Annals of Hematology
- Publication Year :
- 2020
- Publisher :
- Springer Berlin Heidelberg, 2020.
-
Abstract
- Up to 30% of patients with classical Hodgkin lymphoma (cHL) are not responsive to frontline therapy or relapse after primary treatment. In these cases, autologous hematopoietic stem cell transplantation (AHSCT) is the standard of care. The combination of brentuximab vedotin and bendamustine (BV + B) is an effective salvage regimen in this challenging subpopulation. This nationwide multicenter study investigated the real-world efficacy and safety of the BV + B regimen as a bridge to AHSCT in patients with primary refractory or relapsed cHL. A total of 41 cHL patients underwent AHSCT after receiving at least 1 cycle of BV + B (with brentuximab vedotin given at 1.8 mg/kg on day 1 and bendamustine at 90 mg/m2 on days 1–2 every 4 weeks). After a median of 3 (1–6) cycles of BV + B, the objective response rate was 78%, with 29 (70.7%) patients achieving complete remission. Twelve (29.3%) patients relapsed after AHSCT, 2 (4.9%) of them died, while 2 (4.9%) patients are lost to follow-up. After a median of 17 months of follow-up, the estimated 2-year overall- and progression-free survival after AHSCT was 93 and 62%, respectively. Features of advanced disease at recurrence (p = 0.038) and the presence of stage IV cHL at relapse (p = 0.024) are strong predictor markers of unfavorable outcomes. Twenty-four (58.5%) patients experienced adverse events of any grade, while no grade IV toxicities were reported. BV + B is an effective salvage option with a manageable toxicity profile in cHL. The real-world safety and efficacy of this combination are similar to the observations made on the study population.
- Subjects :
- Adult
Male
Neutropenia
Adolescent
Survival
Kaplan-Meier Estimate
Transplantation, Autologous
Young Adult
Antineoplastic Agents, Immunological
Antineoplastic Combined Chemotherapy Protocols
Bendamustine Hydrochloride
Humans
Multicenter Studies as Topic
Antineoplastic Agents, Alkylating
Aged
Retrospective Studies
Salvage Therapy
Hematopoietic Stem Cell Transplantation
Peripheral Nervous System Diseases
Middle Aged
Combined Modality Therapy
Hodgkin Disease
Progression-Free Survival
Treatment Outcome
Drug Resistance, Neoplasm
Positron-Emission Tomography
Bendamustine
Drug Evaluation
Brentuximab vedotin
Female
Original Article
Autologous hematopoietic stem cell transplantation
Hodgkin lymphoma
Follow-Up Studies
Subjects
Details
- Language :
- English
- ISSN :
- 14320584 and 09395555
- Volume :
- 99
- Issue :
- 10
- Database :
- OpenAIRE
- Journal :
- Annals of Hematology
- Accession number :
- edsair.pmid.dedup....4d1f35b08ddb56991c2c9eaab3682a80